A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Clinical trial NCT01905592 · TERMINATED

Trial details

NCT number: NCT01905592
Sponsor: Tesaro, Inc.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Neoplasms, Breast Carcinoma of Breast Human Epidermal Growth Factor 2 Negative Carcinoma of Breast BRCA1 Gene Mutation BRCA2 Gene Mutation Ovarian Neoplasms

Start date: 2014-02-25
Primary completion: 2018-05-23
Enrollment: 216

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.